The primary objective of this study is to evaluate the utility of [99mTc]Tc-hydroxydiphosphonate (HDP) bone scintigraphy in analyzing treatment efficacy in ATTRv amyloidosis patients treated with patisiran and TTR-stabilizers. The gene discussed is TTR; the disease is familial amyloid neuropathy.